Brief: Cyclerion Therapeutics Reports Positive Data For MELAS Treatment At Symposium

Korsana Biosciences

10/06/2022 12:21

June 10 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION THERAPEUTICS ANNOUNCES POSITIVE TOPLINE CLINICAL
DATA
FOR CY6463 IN MELAS PATIENTS AT UMDF MITOCHONDRIAL MEDICINE 2022
SYMPOSIUM
    * CYCLERION THERAPEUTICS INC - DATA FROM AN EIGHT-PATIENT,
OPEN-LABEL STUDY DEMONSTRATE IMPROVEMENTS ACROSS MULTIPLE
BIOMARKERS
    * CYCLERION THERAPEUTICS INC - CY6463 WAS WELL TOLERATED
    * CYCLERION THERAPEUTICS INC - DATA SUPPORT FURTHER
DEVELOPMENT OF
CY6463 IN CNS DISEASES WITH MITOCHONDRIAL DYSFUNCTION
    * CYCLERION THERAPEUTICS INC - NO REPORTS OF SERIOUS ADVERSE
EVENTS (SAES) OR TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS
    * CYCLERION THERAPEUTICS INC - ORAL, ONCE-DAILY
ADMINISTRATION
PROVIDED EXPECTED CNS EXPOSURE

Source text for Eikon:  ID:nGNX4v9ymK 
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))